How Much Wegovy Costs in Korea in 2026

Search Wegovy prices in Korea and you'll find two numbers sitting in the same thread, flatly contradicting each other. One post swears the drug runs about 210,000 KRW a month. The next says 370,000 KRW, before you've even paid the doctor. Here's the thing: both are correct. They're just describing different stages of treatment — and that's the part the screenshots never bother to explain.

The confusion is almost always the same mistake. People quote the starting dose as if it were the long-term monthly cost. It isn't. If you're budgeting for real, the only honest way to do it is to read the full dose ladder first, then add the routine medical costs that ride along with the prescription.

What Wegovy Is, and Why the Korean Price Feels So Scattered

Wegovy is semaglutide, a GLP-1 receptor agonist for chronic weight management. It launched in Korea in October 2024, and for most patients it's still a self-pay drug — no tidy insurance price waiting to settle the argument for you.

So the number you hear swings on three things:

• your current dose
• the clinic and pharmacy route you're using
• whether you mean the drug alone or the full monthly treatment cost

That last distinction is where most of the noise comes from. The gap between an early month and a maintenance month is wide enough to throw off the entire budget on its own.

Korea Dose-by-Dose Price Guide

The most practical way to read the 2026 market is a simple four-week table:

Now you can see why the headline number is so slippery. 210,000 KRW is the figure everyone remembers, because it sounds manageable. 370,000 KRW is the figure that actually matters once treatment settles in.

If you're estimating life past the first few months, budget from the maintenance end, not the entry price. The version of you reading a receipt in month three will be grateful you did.

The most misleading Wegovy number in Korea is the starter-dose number. The month that feels easy at the beginning is rarely the month that defines the long-term budget.

What One Month Really Costs

The pen price is only the first line on the bill. For a patient already on 2.4 mg, a realistic monthly budget in Korea usually looks more like this:

• Wegovy pen: about 370,000 KRW
• follow-up visit: about 30,000 to 50,000 KRW
• periodic lab work: roughly 20,000 to 50,000 KRW when needed
• small supplies: around 5,000 KRW

Add it up and a maintenance month tends to land somewhere around 400,000 to 430,000 KRW, climbing higher in the months that include blood tests or a pricier consultation. That's the number that actually leaves your account on the first — not the one printed on the pen.

The first four months come in cheaper, simply because the dose is still climbing. Run the numbers off the ladder above and medication alone for those four months totals roughly 1,030,000 KRW, before any visit or testing costs.

A First-Year Budget Map

The classic mistake is thinking in single months when Wegovy is really a story about phases. Year one has two distinct cost moods: the ramp-up, then the long maintenance stretch.

This is exactly why the monthly screenshots floating around Korean communities mislead so many people. A starter-month receipt isn't fake. It just doesn't describe the phase that ends up driving the budget.

Wegovy vs. Mounjaro vs. Saxenda in Korea

Korean patients aren't picking Wegovy in a vacuum anymore. A year ago the comparison was murkier; now the options line up cleanly enough to put side by side.

Mounjaro is what makes the Korean pricing math interesting. Its per-dose entry sits above Wegovy's cheapest starter price, but at common maintenance dosing the two land almost on top of each other (369,000 vs 370,000 KRW), so the deciding factor becomes tirzepatide's stronger efficacy profile rather than the sticker. Saxenda can still look cheaper in some clinics, but daily injections and a weaker weight-loss profile change the value calculation for a lot of patients.

What to Ask Before the First Prescription

The most useful questions are the unglamorous ones — and they're exactly the ones nobody asks at the first visit, because they sound boring.

• What will my clinic charge for follow-up visits after the first month?
• How often do you typically repeat blood work in the first year?
• Under what circumstances would you hold a patient at 1.0 mg or 1.7 mg instead of pushing toward 2.4 mg?
• If side effects show up, do you usually slow titration or switch drugs?
• Which part of the bill goes to the clinic, and which part is paid separately to the pharmacy?

Patients who ask these early get fewer pricing surprises later. In a self-pay market, the structure around the prescription matters almost as much as the prescription itself.

Who Can Be Prescribed Wegovy in Korea

Wegovy is generally prescribed for adults who meet obesity-treatment criteria, typically:

• BMI 30 or higher
• BMI 27 or higher with a weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia

The path itself is straightforward:

1. first consultation at an obesity clinic or endocrinology practice
2. weight, BMI, and medical history review
3. blood work when needed
4. start at 0.25 mg
5. increase gradually toward 2.4 mg if tolerated and clinically appropriate

That stepwise climb is the whole reason the first prescription price tells you so little about the long-term budget.

How to Keep the Cost From Drifting Up Further

No tricks here, just a few sensible levers.

Compare total self-pay quotes, not pen prices. Some clinics look cheaper right up until the consultation fee and the add-on tests show up on the invoice.

Ask your prescriber to judge the dose by response and tolerability, not momentum. Plenty of patients stay longer at 1.0 mg or 1.7 mg when the weight trend already looks good and the side effects are already meaningful — there's no rule that says you have to chase the top of the ladder.

And treat private insurance reimbursement as a maybe, not a given, unless your policy clearly spells it out. Coverage terms vary, and Wegovy in Korea still sits in a gray area for a lot of plans. Worth checking. Never worth assuming.

Is Overseas Purchase a Real Option?

In practice, no.

Overseas sellers and informal channels stack three problems on top of each other at once: authenticity risk, storage failures, and zero follow-up if something goes wrong. With injectable semaglutide, the cold-chain issue alone is reason enough to take unofficial import routes off the table. A pen that sat warm in a non-refrigerated parcel for two days — somewhere on a runway in the summer heat — is a pen you simply can't trust.

If you're going to use Wegovy, a formal prescription and local follow-up is still the only route that holds up.

Oral Wegovy Changes the Global Pricing Story, Not Korea's Current One

The big new variable in 2026 is oral Wegovy in the United States. It reshapes the broader GLP-1 market, even though it doesn't yet move what a Korean patient pays this month.

As of April 2026, the approved U.S. tablet strengths are:

• 1.5 mg
• 4 mg
• 9 mg
• 25 mg

And the pricing is more layered than the older summaries let on:

• 1.5 mg starts at about $149 per month
• 4 mg is $149 per month through April 15, 2026, then $199
• higher doses are around $299 per month

Oral Wegovy sets a fresh price anchor for branded GLP-1 therapy. In Korea, though, it's still a future variable rather than a present retail reality. Korean launch timing remains uncertain.

Oral Wegovy matters because it changes the price psychology of the whole category. It does not yet change what a Korean patient pays this week.

Bottom Line

The cleanest working number for Wegovy in Korea in 2026 is this: once you're established on treatment, a month lands around 400,000 to 430,000 KRW after medication and routine care.

The cheaper starter price is real. It's just not the number most patients live with for long. Anchor on the maintenance dose, keep the clinic fees in view, and assume Korea's GLP-1 market stays competitive as oral options and rival brands keep pressing on pricing.

One last practical point. In a self-pay market, planning a year out beats reacting to a headline. The patient who thinks clearly about twelve months makes a better decision than the one who fixates on the first receipt. Wegovy in Korea isn't an impulse buy. It's a treatment commitment with a monthly footprint that shows up on every bank statement, right next to the rent.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app